StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Matinas BioPharma's price to book ratio was 3.3× on Nov 11, 2026, against 10.3× a year earlier. Over the last 5 years it ranged from 2.4× to 60.0×, with a median of 25.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.3×−4.7
2025Dec 31, 20258.0×+5.6
2024Dec 31, 20242.5×−28.0
2023Dec 29, 202330.4×−11.7
2022Dec 30, 202242.1×−14.1
2021Dec 31, 202156.2×−3.3
2020Dec 31, 202059.5×−86.4
2019Dec 31, 2019145.9×+61.2
2018Dec 31, 201884.6×−41.9
2017Dec 29, 2017126.5×−12.9
2016Dec 30, 2016139.4×–

More Matinas BioPharma figures

See a number that looks wrong?